Trial · NCT04998253
Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2
NCT04998253, Early phase 1, Completed, Unidad Temporal COVID-19 en Centro Citibanamex
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2. Trials, record NCT04998253. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04998253
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2
- NCT number
- NCT04998253
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 24 participants, actual
- Lead sponsor
- Unidad Temporal COVID-19 en Centro Citibanamex
- Conditions
- Hypoxic Pulmonary Vasoconstriction, Hypoxemia, Acute Respiratory Distress Syndrome, SARS-CoV-2 Acute Respiratory Disease
- Interventions
- Effects in oxygenation and hypoxic pulmonary vasoconstriction
- First posted
- 2021-08-10
- Last updated
- 2021-08-13
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluation of Oxygenation | 24 and 48 hours | The primary objective of the study is measure the difference in the oxygenation whit two different methods of sedation, inhaled (sevorane) and intravenous (propofol). The oxygenation will be measured whit PaO2 / FiO2 ratio will be used, taking peripheral arterial blood, with FiO2 at 100% one hour after the started of sedation corresponding to each group, again at 24 and 48 hours. |
| Primary | The effect in the hypoxic pulmonary vasoconstriction whit two different type sedation. | 24 and 48 hours | The changes in pulmonary vascular tone and will be measured invasively through a pulmonary arterial catheter (Swan-Ganz) for which the following formula will be used: PVR=(MPAP-LAP)/CO Where PVR = pulmonary vascular resistance (dyn\*s/cm), MPAP = mean pulmonary artery pressure (mm Hg), LAP = left atrial pressure or pulmonary wedge pressure (mm Hg) and CO = cardiac output (L/min). \*79.92 is a constant to equal the units. |
| Secondary | Determination of the anti-inflammatory effect. | 24 and 48 hours | The anti-inflammatory effect will be measured with serum levels of interleukin 6 (IL-6), C-reactive protein (CRP), ferritin, DHL (lactic dehydrogenase), taken by venipuncture on admission, at 24 and 48 hours. |
| Secondary | Measurement of dead space. | 24 and 48 hours | The physiological dead space expressed as a percentage will be calculated using the Bohr formula: DS=(PACO2-PEtCO2)/PACO2 Where DS = dead space, PaCO2 = partial pressure of arterial CO2 in mmHg, PEtCO2 = end tidal CO2 pressure in mmHg. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers38
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04998253
GET https://conductscience.org/api/trials/v1/NCT04998253/papers?page=2